Neluxicapone
(Redirected from Draft:Neluxicapone)
 | |
| Clinical data | |
|---|---|
| Drug class | Catechol O-methyltransferase inhibitor |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C16H12N2O2 |
| Molar mass | 264.284 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Neluxicapone (INN) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024.[1][2][3] The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone.[4][3] COMT inhibitors are used in conjunction with levodopa in the treatment of Parkinson's disease.[4] Neluxicapone was first described in the literature by 2018.[3][1] Its INN was designated by the World Health Organization (WHO) in 2019.[2]
References
[edit]- ^ a b The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2018 (StemBook2018) (PDF). World Health Organization. 2018. No. WHO/EMP/RHT/TSN/2018.1.
-capone catechol-O-methyltransferase (COMT) inhibitors. entacapone (65), nebicapone (96), neluxicapone (119), nitecapone (62), opicapone (103), tolcapone (66)
- ^ a b World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81" (PDF). WHO Drug Information. 33 (1): 43–133.
- ^ a b c "Neluxicapone". PubChem. U.S. National Library of Medicine. Retrieved 8 October 2024.
- ^ a b Haasio K (2010). "Toxicology and safety of COMT inhibitors". International Review of Neurobiology. 95: 163–189. doi:10.1016/B978-0-12-381326-8.00007-7. ISBN 978-0-12-381326-8. PMID 21095462.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |